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ABSTRACT 
The pathogenesis of OA and CVD is currently related to inflammatory processes. It is 
unknown how OA and its surgical treatment impact the cardiovascular system. 
Hypotheses 
We hypothesized that (1) THA patients more than 5 years after the index surgery have an 
increased risk for cardiovascular morbidity and mortality compared with the general 
population and (2) that late cardiovascular risk following THA may be mediated by the 
development of osteolysis and systemic inflammation. Furthermore, we hypothesized that 
patients with asymptomatic osteolysis after THA (3) are more likely to develop CVD and 
(4) have a higher burden of cardiovascular risk markers than patients without periacetabular 
osteolysis. 
Aims of the studies 
The general aim of this thesis was to investigate patients treated with THA due to OA and 
patients treated with THA who subsequently underwent revision surgery and the associated 
risk of cardiovascular morbidity and mortality. Further aims were to compare patients with 
and without periacetabular osteolysis regarding CVD and cardiovascular risk markers. The 
specific aims were as follows: 
Paper I: to determine whether there is a late correlation between THA and cardiovascular 
events. 
Paper II: to compare patients after revision surgery due to aseptic loosening of the implant 
to controls (patients not having revision surgery) regarding the risk for cardiovascular 
morbidity and mortality and the time to first event during the exposure period.  
Paper III: to investigate whether THA patients with asymptomatic periacetabular osteolysis 
have an increased long-term risk of CVD compared to THA patients without osteolysis and 
the time to event. 
Paper IV: to compare THA patients with and without periacetabular osteolysis regarding 
cardiovascular risk markers and electrocardiography findings. 
Materials and methods/results 
Paper I: This was a nationwide, matched cohort study with data on 91,527 OA patients who 
underwent surgical treatment. Data were obtained from the Swedish Hip Arthroplasty 
Register. A control cohort consisting of 270,688 patients from the general Swedish 
population was matched at a ratio of 1:3 to each case by sex, age, and residence. The mean 
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follow-up time was 10 years. Patients with surgically treated OA of the hip had an increased 
risk of cardiovascular morbidity and mortality many years after the operation compared with 
controls. 
Paper II: This was a nationwide, nested, case-control study consisting of 14,430 patients 
undergoing cemented THA due to OA between the years 1992 and 2005. The case group 
consisted of 2,886 patients who underwent reoperation on the treated hip due to osteolysis or 
aseptic loosening at any time within five years after the index surgery. Each case was 
matched with four controls (11,544). Patients with OA who underwent THA and 
subsequently underwent revision surgery due to loosening had a higher risk of developing 
cardiovascular events than controls. 
Paper III: This was an observational cohort study of 139 patients who underwent 
uncemented THA between 1992 and 2007. All patients were assessed by CT of the affected 
hip to sort patients into 2 groups, those with periacetabular osteolysis (cases=33) and those 
without periacetabular osteolysis (controls=106). There was a higher rate of CVD among 
THA patients with periacetabular osteolysis than among THA patients without periacetabular 
osteolysis but no statistically significant risk increase. 
Paper IV: This was a cross-sectional study consisting of 108 patients who underwent THA 
(uncemented components) due to OA between 1992 and 2007. All patients were assessed by 
CT of the affected hip. Patients with periacetabular osteolysis constituted the cases (n=19) 
patients without periacetabular osteolysis (n=89) were selected as controls.(89) Markers of 
inflammation, risk markers for CVD and ECG abnormalities were collected and compared 
between the groups. There was no difference in the risk burden for CVD many years after 
THA between patients with and without periacetabular osteolysis. 
Conclusions: Patients with surgically treated OA of the hip have an increased risk of 
cardiovascular morbidity and mortality many years after the operation. Patients who undergo 
revision surgery due to aseptic loosening and/or osteolysis have a higher risk of developing 
cardiovascular events. These observations may be indicative of common disease pathways. 
Furthermore, while the risk for CVD in patients with periacetabular osteolysis is slightly 
higher, there is no significant difference in the risk burden for CVD compared with patients 
without periacetabular osteolysis. The examination of a larger sample and the use of 
comparable durations after surgery are recommended. 
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SAMMANFATTNING PÅ SVENSKA 
 
Total höftledplastik är en vanlig behandling för höftledsartros när konservativ behandling inte 
givit resultat. Långtidsuppföljning av hjärt-kärlsjukdom efter total höftledsplastik har tidigare 
ej varit föremål för vetenskapliga studier. Det är heller inte klarlagt hur artros och dess 
kirurgiska behandling påverkar det kardiovaskulära systemet. Den främsta orsaken till 
omoperation på lång sikt efter en höftplastik-operation är osteolys. Orsaken till osteolys är 
inte säkert klarlagd men den dominerande hypotesen är att slitageprodukter från de 
konstgjorda materialen leder till en låggradig inflammation i vävnaden runt protesdelarna 
vilket leder till lossning av desamma. En omoperation pga osteolys är ofta omfattande och 
riskfylld. Aterosklerotisk hjärtkärlsjukdom betraktas också som en inflammatorisk sjukdom 
med låggradig inflammation i kärlväggen till följd av åderförfettning. Det kan finnas ett 
samband mellan dessa tillstånd, t ex genom att osteolys stimulerar den inflammatoriska 
processen i blodkärlen och på så vis bidrar till utveckling och progress av ateroskleros. En 
annan förklaring skulle kunna vara att patienter som både har osteolys och ateroskleros har en 
benägenhet att utveckla inflammation i flera organsystem. 
Vårt syfte med följande studier var att undersöka möjliga samband mellan operation för 
osteoartros med total höftledsplastik, osteolys efter denna operation och senare risk för 
hjärtkärlsjukdom.  
Målet för delarbete I var att undersöka om total höftledsplastik pga artros ökar långtidsrisken 
för hjärtkärlsjukdom och död. Efter 9 till 13 års uppföljning hade gruppen som erhållit 
höftprotes högre risk för död i hjärtkärlsjukdom, de hade också en högre andel 
återinläggningar på sjukhus till följd av hjärtkärlsjukdom.  
I delarbete II jämförde vi patienter som blivit omopererade pga peracetabulär osteolys inom 
fem år efter operation med total höftledsplastik med en kontrollgrupp som erhållit höftprotes 
men ej blivit omopererade. Vi jämförde förekomst av hjärtkärlsjuklighet samt tiden till första 
hjärtkärlhändelse. Det visade sig att patienter som genomgått en omoperation pga aseptisk 
lossning/osteolys hade högre risk än förväntat att drabbas av hjärtkärlsjukdom jämfört med 
patienter som ej opererats för aseptisk lossning.  
I delarbete III och IV jämförde vi patienter med periacetabulär osteolys med patienter som ej 
hade periacetabulär osteolys. Alla patienter hade genomgått total höftledsplastik pga 
osteoartros mellan 1992 och 2007. Samtliga undersöktes med skiktröntgen för att påvisa 
förekomst av osteolys. Vi jämförde antalet hjärtkärlhändelser samt tiden till första 
hjärtkärlhändelse mellan grupperna. Vidare undersökte vi halter av högsensitivt CRP, vita 
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blodkroppar samt blodfetter vilka har visat sig vara prediktorer för hjärtkärlsjukdom. 
Samtliga patienter undersöktes även med EKG då vissa EKG-förändringar kan förutsäga 
ökad risk för hjärtkärlsjukdom. Vi kunde inte visa några statistiskt signifikanta skillnader 
mellan grupperna.  
I sammanfattning visar studierna på en association mellan total höftledsplastik och senare risk 
för kardiovaskulär sjukdom och död under långtidsuppföljning samt också en koppling till 
högre risk för hjärtkärlsjukdom hos patienter som genomgått omoperation på grund av 
osteolys/lossning av den konstgjorda ledpannan än för patienter som inte är omopererade. 
Däremot fann vi ingen koppling mellan osteolys och kardiovaskular sjukdom eller 
riskmarkörer för kardiovaskulär sjukdom hos en mindre grupp patienter med osteolys efter 
total höftledsplastik jämfört med patienter utan osteolys efter höftprotes-operation. Hur 
kopplingen mellan total höftledsplastik, osteolys och hjärtkärlsjukdom ser ut och eventuellt 
kan förklaras återstår att visa. 
 
 
 
 
 
  
 
 
 
 
 
 
   9 
BACKGROUND OSTEOARTHRITIS 
OA is a degenerative, progressive joint disease that leads to the degradation of cartilage and 
subchondral bone. The word osteoarthritis is derived from the Greek: 
osteo meaning “of the bone” 
arthro meaning “joint” 
itis meaning “inflammation” 
Epidemiology  
OA occurs mostly later in life and tends to be slowly progressive. It is by far the largest 
reason of pain in working-age population (1) and in the elderly.(2, 3) Knees, hips, and hands 
are normally affected. Prevalence ranges between 12% (4) to 22%.(5) From the age of 40 
onwards, the risk of developing OA increases.(6) The incidence and prevalence are higher in 
developed countries.(7) Pain and disability are the main symptoms. For the individual, 
mobility and activities of daily living are reduced and in addition; discomfort, low self-worth, 
and loneliness.  
Risk factors 
There are risk factors, increasing the risk of developing OA.(8) They are mainly as follows: 
sex, age, obesity, diet, joint injury, and occupation.  
Sex: Women have a higher risk of developing OA in the hand, foot, and knee.(9) The 
increased incidence is shown at the time of menopause, and this has led to hypotheses 
regarding the role of estrogen. The results of other studies are inconsistent, and the 
difference could be ascribed to other factors, such as bone strength.(10, 11) 
Age: One of the main prognosticators of OA is age.(12) The mechanism that leads to the 
increased prevalence and incidence is not fully understood. It is probably a combination of 
multifactorial changes, including weakening of muscles, thinning of cartilage, biological 
changes, and decreased proprioception.(13, 14) 
Obesity: With increases in prevalence worldwide, there are also reasonable indications that 
obesity is one of the most extensive risk factors for OA in not only the knee but also the hand 
and hip, with a dose-response gradient with increasing BMI.(15, 16) The risk increases by 
35% for every 5-unit increase in BMI and is higher in women than in men. The association 
between hip OA and high BMI is weaker but still present.(17) Bilateral, but not unilateral, 
disease in the hip is clearly associated with being overweight. Hand OA is associated with 
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obesity.(18) The impact of obesity may not just be biomechanical but may also be associated 
with metabolic syndrome (19) and inflammatory systemic effects. 
Diet: Nutritional factors may have an influence on the development of OA through a 
variety of mechanisms. Many laboratory and observational studies confirm this feasibility. 
High dietary intake of micronutrient antioxidants may protect against tissue damage and 
could theoretically protect against OA. The Framingham Knee OA Cohort study found that 
persons with a low vitamin C intake had an enlarged risk for developing radiographic and 
painful OA.(20) Bone metabolism is reliant on on the presence of vitamin D.(21) Low 
levels of vitamin D in tissues can promote the process of OA. The Framingham study 
reported an increased risk for the progression of radiographic OA in patients with a low 
intake of vitamin D.(22) Reversely, the Framingham study mentioned above reported no 
evidence that high antioxidant intake reduces the incidence of knee OA.(20) 
Joint injury: Injuries are commonly associated with damage to the cartilage, subchondral 
bone. Tibial plateau fracture leads to radiological evidence of post-traumatic OA in 25%-
45% of cases on long-term follow-up.(23-25) Malalignment of the joint has also been shown 
to promote the progression of OA.(26) 
Occupational: Repetitive joint movements have been correlated with an increased risk of 
OA. Individuals in occupations requiring squatting or kneeling have twice the risk of 
developing knee OA than those in professions not requiring any physical activity. Hip OA 
has also been associated with standing for a long time and lifting.(27) 
 
Pathophysiology 
OA is a slow process of remodeling cartilage and sub articular bone(28). Development takes 
typically many years. The disease is characterized by degenerative structural changes in joint-
osteophyte formation, laxity of ligaments, weakening of muscles surrounding the joint and 
low-grade synovial inflammation. Several attempts have been made to clinically and 
radiographically define OA; not rarely with low levels of agreement between them.(29) The 
cartilage undergoes degradation, bone remodels by responding actively to the inflammatory 
process in surrounding tissues. Increased activity of several cytokines and chemokines (30) in 
the joints, drive production of enzymes that mediate destruction of cartilage. 
Diagnosis 
The diagnosis of OA is dependent on clinical and radiological features. Patient´s history 
and clinical examinations of the affected joint together with plain radiographs is crucial. 
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Pain, stiffness and disability are clinical symptoms. OA on plain radiographs is 
characterized by reduction of joint space, presence of osteophytes, subchondral cysts and 
subchondral sclerosis, (Figure 1). Early painful OA may not have radiographic changes, and 
conversely, patients with severe radiographic signs may be entirely without symptoms. The 
association existing between severity of OA signs on radiographs and clinical symptoms is 
not strong.(29)   
 
 
 
 
  
Figure 1. Early osteoarthritis of the hip.  
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Treatment 
Conservative therapy should always be initiated—analgesics, physiotherapy, ambulatory aids 
and weight loss. The surgical indication for hip replacement requires severe pain in the 
affected joint, loss of function, physical findings on examination and the presence of OA on 
radiographs. The surgery aims to replace the degenerated joint surfaces, with an artificial 
joint, i.e., total hip arthroplasty (THA),(Figure 2). 
 
 
Figure 2. THA, uncemented components. 
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The term “arthroplasty” is derived from two Greek words: (a)“arthro”, meaning joint, and 
(b) “plastikos”, associated with moulding.(31) 
• Painful OA is the main indication for THA. Other indications are as follows: 
• Rheumatoid arthritis. 
• Post-traumatic OA due to previous hip injury or fracture. 
• Avascular necrosis of the femoral head. May occur after injury. It is also associated 
with long-term use of steroid medications and excessive alcohol intake. 
• Developmental dysplasia of the hip, also called hip dysplasia. It is a congenital 
condition of disturbed development. It ranges between minor laxities of the hip to a 
complete dislocation of the joint. Children are treated, but painful OA in this patient 
group is common in adulthood. 
• Displaced femoral neck fractures in some patient groups, depending on age, previous 
mobility, etc. 
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TOTAL HIP ARTHROPLASTY 
History 
Joint pathology has been identified as OA in ancient skeletons, with a prevalence and 
distribution seemingly similar to those of today. Roman(32), Mediaeval and Saxon(33) 
populations with OA have been found on archaeological excavations in Britain. Surgeons 
have been searching for more than two hundred years to find a treatment for the painful 
condition that OA can become,(34) and treatment has evolved from joint excision and 
osteotomy to modern THA. At the end of the eighteenth century, removal of the femoral head 
was practiced for many joint diseases. Anthony White (1782-1849) performed the first 
excision arthroplasty in 1821 in London. Patients still had some mobility but lacked 
stability.(35) Other surgical attempts made to treat OA have included arthrodesis of the joint, 
osteotomy,(36) nerve division, calcium deposition and joint lavage. There was a broad search 
for materials that could be used to resurface or even replace the hip joint. Professor 
Themistocles Glück presented the first recorded trial of hip replacement at the 10th 
International Medical Conference in Germany in 1891. Ivory was used to replace the femoral 
heads of 14 patients whose joints were destroyed by tuberculosis.(37) All patients suffered 
later from chronic infection; subsequently, Glück declared that joint infection is a 
contraindication to joint replacement. In Czechoslovakia, the surgeon Vitezlav Chlumsky 
(1867-1943) started experiments with interpositional materials to replace the worn joint 
surfaces. Silver plates, rubber struts, magnesium, zinc and other materials were used. Other 
tested materials included skin, fascia lata and even pig bladder submucosa. The materials 
were placed between the articulating surfaces of the hip. The first mould arthroplasty was 
performed with glass in 1925, formulated by the American surgeon Marius Smith-Petersen. 
The prosthesis consisted of a hollow hemisphere that could conform over the femoral head 
and provide a clear surface for movement. Although glass is a biocompatible material, it did 
not have the strength to resist the forces going through the hip joint and crushed. Bone 
resorption, soft tissue reactions and aseptic loosening were the main problems. In 1936, two 
metallurgists, Charles Venable and Walter Stuck, fabricated a cobalt-chromium alloy, 
subsequently named vitallium. It was promptly applied in orthopaedics; the alloy was strong 
and resistant to corrosion, and it has been used in various prostheses since. The metal turned 
out to be a success, but the resurfacing technique was still not satisfactory. The hunt for better 
materials and ways to fix the prostheses continued. Smith-Peterson and Wiles were the 
forerunners of a new era of arthroplasty in 1938, when the first prosthetic total hip 
replacement procedure was performed.(38) A reshaped femoral head covered by a vitallium 
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cup composed the interposition. During these early years, different groups tested a plethora of 
materials, varying from stainless steel and cobalt to rubber, glass, and even ivory.(36) 
Mechanical failure and catastrophic complications were common due to poor designs and 
inferior materials. In Paris, two brothers (Judet) tried to replace the painful arthritic hip 
surfaces with an acrylic material “borrowed” as a material from dentists. The acrylic had a 
blank surface, but disastrously became loose. Efforts were made to fix the cup to the bone, 
which improved the results, leading to an early form of the modern solution of fixing the cup 
to the bone. In 1942, Austin T. Moore from South Carolina designed a replacement for the 
entire femoral head. Primarily, it was used to treat femoral neck fractures, but it was also used 
in some cases of OA. This kind of hip replacement, named hemiarthroplasty, only addressed 
the damaged articular surface of the femoral head. The worn-out surface of the acetabular 
cartilage was not restored. The prosthesis consisted of two pieces; one metal ball that was fit 
into the acetabulum and a metal stem that was inserted into the proximal femur. Due to the 
still arthritic destruction of the acetabulum, the results were not acceptable. There was still no 
sufficient technique for fixing the femoral stem to the bone; many patients suffered from pain 
due to loosening of the implant. In 1947, the Judet brothers designed an acrylic femoral head 
prosthesis made of polymethylmethacrylate (PMMA). This material is still used today but as 
bone cement, not as an articular surface due to the high risk of femoral neck fracture. The 
first metal-on-metal (MoM) prosthesis was used by the English surgeon George McKee. In 
1953, the Thompson stem was used with a new one-piece cobalt-chrome socket as the new 
artificial acetabulum. In the 1960s, Sir John Charnley introduced and revolutionized the 
management of the arthritic hip. He contributed to the evolution of total hip replacement in 
three ways: 1) presenting the idea of low-friction torque arthroplasty; 2) fixing the 
components to the upper end of the femoral shaft with acrylic cement; and 3) introducing a 
high-density polyethylene (PE) cup cemented into the drilled-out acetabulum as a bearing 
material.(39) This method was defined and named “low-friction arthroplasty”. Periprosthetic 
joint infection is a disastrous complication; Charnley constructed a filtered air enclosure in 
the operating theatre with special suits for the team to address this complication. The 
infection rate decreased dramatically. Reports of implant survivorship showed 81% and 77% 
at the 25-year follow-up.(40, 41) Charnley and colleagues are responsible for the 
understanding of modern THA advancing from a salvage procedure with poor long-term 
outcomes to one of the best and most frequently used elective surgeries. The technique used 
today does not differ dramatically from the one he described. In 1991, THA was named “the 
operation of the century”.(42) 
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Epidemiology  
Over 1.5 million THA procedures are performed every year worldwide.(39) This represents a 
milestone in orthopaedic surgery. THA is an effective surgical treatment for 
relieving hip pain and improving physical function caused by OA. The results are excellent, 
and the treatment is generally regarded as the standard procedure when physiotherapy and 
non-surgical treatment have failed. The main objective for THA is to relieve pain, improve 
function and provide a higher quality of life for the individual. Worldwide, 1.7 million THA 
procedures were performed in 2013.(43) The number is expected to grow; between 2005 and 
2010, the number of THA procedures increased by 16%.(44) The amount of primary THA 
procedures in the US is likely to grow by 174% between 2005 and 2030 (572,000 surgeries 
per year).(45) In Sweden, the incidence of these surgeries is also growing steadily. In 2018 in 
Sweden, 18,629 patients underwent primary THA (46), (Figure 3). One natural explanation 
for the growing incidence could be the longer life expectancy, and thus the increasing number 
of elderly people. There are complications after THA, and they can simply be divided into 
early and late. Some, such as dislocation, deep joint infection and usually periprosthetic 
fracture, require surgical treatment. Thromboembolism, nerve injury, leg length discrepancy 
and heterotopic ossification are treated non-surgically. 
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Figure 3. Incidence of THA in Sweden 1970-
2018. Reprinted with permission from the 
SHAR. 
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Arthroplasty registries 
The National Registry Committee in France, 1995, defined a registry as “a continuous and 
exhaustive collection of nominative data about one or more health-related events in a 
geographically defined population, by a team having specific expertise, to be used for 
research and public health studies”.(47) Data on patient implants are systematically collected 
for all THA procedures in Sweden performed in both private and public hospitals. Sex, age, 
diagnosis, surgical technique and date of surgery are recorded. Revision surgery is used as an 
endpoint. Only “revision surgery” is used to classify prosthesis as having “not survived”. The 
definition of “revision surgery” by the Swedish Hip Arthroplasty Register (SHAR) is quite 
exact: “any surgical procedure during which one or more prosthesis components are replaced, 
removed or added”. This makes it possible to analyse the complications in detail. Centrally 
collected and analysed data can offer a rapid understanding of when used products lead to 
complications. Additionally, it is possible to find the affected individuals and quickly 
withdraw the products from the market. The essential method to estimate the results of 
surgery is Kaplan-Meier survival analysis with revision surgery as the endpoint; therefore, 
implants must be connected to individual patients, and it is vital to be able to plot survival 
curves. The two most common reasons for revision surgery are aseptic loosening and 
infection, (Figure 4). In some countries that do not permit individual connections to implants, 
outcomes are presented as the rate of revisions per 100 component years. Registries provide 
data not only for epidemiological and demographic studies but also for comparisons of 
outcomes of different kinds of implants and clinics within a country. Revision surgery and the 
decision to perform surgery in individual cases depend on many factors that are of the utmost 
most importance to the patient’s health status. Patients may thus have complications 
postoperatively without undergoing revision surgery due to high risk or other reasons. 
Therefore, using revision surgery as the only endpoint is problematic. Patient-reported 
outcome measures; (PROM) include evaluations of pain, function, quality of life and patient 
satisfaction are collected in line with those of the survival analysis to further assess the results 
of hip replacement.  
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Figure 4. Reasons for reoperation in Sweden 1998-2018. Reprinted with permission from SHAR.  
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Components and materials 
A standard THA typically consists of four individual components, (Figure 5). The stem is the 
part of the prosthesis that is inserted into the proximal femur. The proximal part (top end) of 
the femoral stem is called the trunnion. It is taper shaped, for the femoral head to wedge onto. 
The femoral head is held in place on the trunnion with friction. The femoral head, which can 
be in different diameters, fits into the analogue size of the cup. The cup is inserted into the 
acetabulum. Types of arthroplasty are usually referred to methods of fixation, cemented or 
uncemented. In Sweden (46), the cemented technique is the most common. The cement 
creates an interlocking fit between the implant and the bone. Uncemented implants have 
surface features considered to bone ingrowth (48) and biological fixation over time.  
 
Figure 5. THA components. Uncemented on the left, cemented on the right. 
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Materials commonly used in THA 
Metallic alloys 
The most common alloys used in implant components are stainless steel, cobalt-chromium 
alloy, and titanium alloy. The materials must keep high strength, elasticity, ductility, and 
resistance from corrosion, and biocompatibility. 
Polyethylene 
Polyethylene (PE) is a widely used material in hip replacement liners, and the introduction of 
highly crosslinked PE (HXLPE) in THA has been one of the most important improvements 
since introduction in the late 1990s. The purpose was to reduce wear-induced periprosthetic 
osteolysis and loosening. It is created by radiation and reheating PE, which induces cross-
linking between PE molecules. During cross-linking free radicals are formed, resulting in 
making the HXLPE exposed to oxidative degradation and material embrittlement. To 
diminish this process the antioxidant vitamin E may be added to the PE, which binds to free 
radicals and by this diminishes the oxidation process and wear. The change to HXLPE in 
acetabular liners has contributed to a dramatic reduction in wear compared to PE.(49-51) 
Ceramic materials were introduced in THA in the 90´s to address the problem of PE wear 
(52) due to it´s high resistance to scratch. Ceramics is neither a metal, nor a semiconductor or 
a polymer. The problem with older ceramic implants was development of cracks that could 
lead to implant failing abruptly by fracturing.(53) Modern ceramics show fewer 
complications with failure.(54) 
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Bearings 
Bearing materials in articulating surfaces of the hip prosthesis may consist of PE, metal or 
ceramic. The surfaces should have a low production of wear particles and low coefficient of 
friction. The most common used articulations are combinations of a hard metal or ceramic 
head and a soft liner of PE-“hard-on soft articulation”. Metal-on-PE (MoP) or ceramic-on-PE 
(CoP) are the most used materials in THA articulations in Sweden. “Hard-on-hard” articular 
combinations consist either of metal-on-metal (MoM) or ceramic-on-ceramic (CoC). MoM 
bearings showed improved wear features in the 1990s, resulting in 35% of all bearings used 
in the US in the early 2000s. A growing failure rate was observed in joint registries in 2010s 
(55, 56) A comprehensive amount of clinical situations from small tissue lesions to large 
bone destructions were reported describing periprosthetic tissue infiltration by inflammatory 
cells (57), necrosis and metallic debris. The condition has many labels such as; aseptic 
lymphocytic vasculitis-associated lesions (ALVAL) metallosis (58), and 
pseudotumours.(59, 60) Clinical symptoms are pain, due to tissue damage; possible 
loosening of implants which eventually may lead to revision surgery. Besides local 
reactions, metal ions in serum have been linked with systemic responses and toxic effects 
on organs are reported.(61) There is no definition of safety levels of metal ions in serum 
regarding the potential toxic accumulation of metal products in organs. CoC bearings show 
low wear rates not only due to the materials hardness but also because of a reduced 
inflammatory tissue reaction from wear particles released. Disadvantades with the bearing 
include fracture of the material and squeaking.(62) 
 
Cement and fixation 
“Bone cement” is extensively used for the fixation of implants in various orthopaedic and 
trauma surgeries. It was developed in the late 1950s. The real substance is PMMA, which is 
an acrylic polymer formed by mixing two sterile components: a powder and a liquid. The 
powder consists of the cement (acrylic) polymer together with an initiator (di-benzoyl 
peroxide). A radio-opacifier (zirconium oxide or barium sulphate) is added for visibility on 
X-ray, and an antibiotic is usually added. It is the viscosity of the cement that enables 
manipulation of the cement during the surgery. It has the function of grout between the 
cancellous bone and the implant Heat is generated due to an exothermic reaction. The cement 
has no adhesive effects, so it does not live up to the definition of cement, i.e., “a substance 
that bonds two things together”. Although the chemical composition of bone cement has 
essentially remained the same over the years, the cementation technique has changed, 
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which has significantly improved the results.(63) The cement has the role of space filler, 
creating a close-fitting mechanical interlock holding the implant to the irregular bone surface. 
Thus, there is no adhesive bond attachment between the bone and the prosthesis. Thermal and 
chemical damage to the bone during the cementation process leads to formation of 
granulation tissue and an interface created between bone and the cement. The cementing 
technique is good to use in osteoporotic bone and antibiotics can be added as prophylaxis to 
reduce the risk of postoperative infection. The cement cures quickly which enables rapid 
patient rehabilitation. In rare cases, peroperative during cement implantation cement in its 
liquid phase can enter the bloodstream before curing and cause bone cement implantation 
syndrome (BCIS).(64) There is no consensus regarding definition of the condition, which 
includes hypoxia, (65)hypotension, (66) cardiac arrhythmia, (67) increased pulmonary 
vascular resistance and cardiac arrest.(68)   
Cementless fixation  
Due to the problems with wear and loosening an alternative to uncemented implants was 
introduced in the late 1970s. Cementless components were designed to grant sufficient initial 
stability. The technique used to fix a cementless prosthesis is called press fitting. The 
implants are inserted with physical force on the prosthetic part so the maximal press-fit to the 
peri-implant host bone can be obtained. Once the implant is stabilized in the bone, the 
components allow the physiological transmission of biomechanical forces through the joint. 
The surface of the prosthesis is rough and/or has a porous coating allowing close bony 
juxtaposition. Initial research was performed to find a coating capable of enhancing bone 
ingrowth, i.e., osseointegration. This term thus describes the direct structural and functional 
connection between living bone and the surface of a load-bearing artificial implant, (69) with 
load bearing as defined by Albrektsson.(70) Bone formation is initiated around the prosthesis 
due to a series of biological events. Early postoperatively there is micromotion between the 
implant and the bone; an interface is formed between bone and the implant. With time peri-
implant bone remodels according to the man made new biomechanical situation, the implant 
surface is replaced by new bone.(71-73) Hydroxyapatite is currently the most frequent used 
material on uncemented implants due to its similarity and biocompatibility to bone.(74) 
Problem of wear 
Wear is the result when damage or removal occurs of material from one or both of two solid 
surfaces under loading in moving contact, followed by the release of particles. There are 
different types of wear: adhesive wear, abrasive wear, third body wear and linear wear. In 
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adhesive wear, the weaker surface of the two opposing surfaces transfers onto the stronger 
and harder surface. Abrasive wear develops when rough areas on the surface of the stronger 
material form grooves in the softer surface or if free particles (cement, bone, metal or PE) are 
embedded between two bearing surfaces during motion. Linear wear is defined as the degree 
of penetration of the prosthetic head into the PE liner. Despite the material or design, artificial 
joints generate particles due to wear and the biological activity is highly dependent on the 
characteristics and quantity of wear particles. All by-products from currently used implants 
cause an inflammatory response to a greater or lesser degree (75, 76), which involves 
macrophages in particular, as well as fibroblasts, lymphocytes and osteoclasts. Type, size and 
density of material change the host’s overall cell and tissue response.(77) PE particles range 
in size from 0.1 to 10 µm, and those between 0.1 and 0.5 µm are suggested to be most 
biologically active. The wear rate per year in mm of PE is associated with the development of 
osteolysis and its volume.(78, 79) 
Osteolysis 
Osteolysis happens when resorption of peri-implant bone occurs. It is a common and serious 
complication of THA on the long term.(80) Bone tissue undergoes lifelong continuous 
turnover and remodeling.(81) The constant ongoing process involves osteoclasts removing-
resorption, and osteoblasts rebuilding (82) bone-ossification. If imbalance happens in the 
process of bone turnover and osteoblast activity increases it may lead to bone resorption, peri-
implant osteolysis and subsequent aseptic loosening. If pressure in the joint space increases, 
the wear particles migrate out to spaces with lower pressure and diffuse from the peri-implant 
area into tissues around the joint.(77) Joint fluid containing particles is driven out to new 
periprosthetic areas and therefore drives the total spread of osteolysis and increases both peri-
implant bone resorption and bone stock weakening.(83) The destruction of peri-implant bone 
tissue is progressive and loosening may subsequently occur.(84) Initially radiolucent lines 
and/or cavitation in the periprosthetic bone interface (85) can be detected on radiographs as 
insular areas of bone resorption. Willert and Semlitsch were the first presenting the theory of 
aseptic loosening of cemented implants as a result of wear by particles.(86) It was initially 
called “cement disease”. Later it was named “particle disease” by Dr William Harris.(87) The 
osteolytic lesion can develop in diverse forms in the peri-implant bone tissue, and can 
develop into large volumes. As long as the implant is stable there are no clinical symptoms, 
early symptoms of a loose and unstable implant may present as pain in groin and buttock. As 
the osteolysis progress subluxation and dislocation may occur. Several classification schemes 
have been proposed to describe periacetabular osteolysis and bone loss in revision THA.(88-
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90) The Paprosky classification is a comprehensive and widely used, due anatomical 
orientation on the location and amount of bone loss, it is used as treatment recommendation 
when surgery is indicated. Surgery is associated with high patient morbidity and 
mortality.(80) 
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Imaging modalities  
Radiographic methods are essential in assessing osteolysis. Consecutive radiographs are 
needed to detect and measure advancement. Initially the osteolytic lesions on plain 
radiographs are hard to detect. Therefor computed tomography (CT) is a more precise method 
to evaluate the extension of the peri-implant osteolysis regarding the location, implant 
position, volume and amount of bone loss, (Figure 6). Various descriptions have been made 
to describe and define periacetabular osteolysis on CT (91, 92) and there is still no consensus. 
Definition of periacetabular osteolysis in this project was defined as a defect with loss of 
bone trabeculae in direct connection to the surface of the acetabular component and its 
volume was measured in cm3. Magnetic resonance imaging (MRI) offers a higher soft tissue 
contrast than radiography and CT. Soft tissue conditions not detected by plain radiographs 
and CT may be visualized by MRI, and clarify failure.(93) Several methods have been 
developed to assess PE wear.(94, 95) To evaluate prosthetic movement and potential failure 
of implant consecutive radiographs are compared with three-dimensional measures using 
image-processing software. Radiostereometric analysis (RSA) developed in 1970s by Selvik 
et al. is considered the most precise method to detect relative changes over time in implant 
position.(96) It not only evaluates implant stability but also wear of the PE liner. 
Peroperatively small tantalum beads are embedded in the periprosthetic bone. Their position 
used as a reference can discover movements of the prosthetic components.  
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Figure 6. CT image of uncemented THA, periacetabular osteolysis. 
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CARDIOVASCULAR DISEASE 
CVD relates to the circulatory system, which includes the heart and blood vessels. 
Cardiovascular events refer to any vascular incident that causes damage to the heart muscle. 
CVD comprises many types of conditions; some of them might develop at the same time or 
lead to other conditions or diseases in the group. The major CVD are as follows: 
- Coronary heart disease (disease of the coronary arteries supplying the heart) 
- Cerebrovascular (disease affecting arteries supplying the brain) 
- Peripheral arterial disease (disease of the arteries supplying the extremities) 
Epidemiology  
CVD is by far the largest cause of death globally, causing an expected number of 17.9 million 
deaths every year. In 2016, 31% of all global deaths were represented by CVD. Of these 
deaths, 85% were due to myocardial infarction and stroke. One-third of these deaths occur in 
people younger than 70 years of age. Over 75% of CVD-related deaths occur in low- and 
middle-income countries.(97) CVD can be avoided by changing and reducing behavioural 
risk factors, including the use of tobacco, unhealthy diet/obesity, and a lack of physical 
inactivity.(98) Risk factors for CVD are several. Patients affected by hypertension, diabetes 
mellitus, and hyperlipidaemia) should receive treatment to prevent CVD and premature 
death. It is also known that addition of CVD risk factors alters the vascular risk.(99) 
Pathophysiology 
The process of atherosclerosis is characterized by progressive thickening and hardening of 
large and medium-sized arteries and is most often a consequence of lipid deposits in the inner 
lining of the artery, called the intima layer. It is characterized by vascular obstruction from 
lipid deposits, which results in reduced blood flow. Previously, it was considered of as a 
disorder of age and cholesterol. Currently; it is seen as the result of a multifaceted interaction 
between inflammation and lipids. Atherosclerosis is the most common cause of CVD; it starts 
with the development of atherosclerotic plaques. Atherogenesis mainly occurs in the inner 
layer of arteries called the intima, especially where arteries divide. High levels of total 
cholesterol, low-density lipoprotein (LDL) and triglycerides and low levels of high-density 
lipoprotein cholesterol have been associated with CVD morbidity and mortality in many 
studies.(100, 101) 
  28 
Cardiovascular disease and inflammation 
LDL particles cause atherosclerosis. The endothelium exposed to accumulate LDL particles 
is a major element of disease initiation and progression.(102) Accumulated LDL particles in 
the intima undergo modifications rendering them pro-inflammatory (103) and immunogenic 
features. There are several cells driving plaque inflammation, including immune cells, 
smooth muscle cells, platelets, and endothelial cells. Monocytes penetrate the endothelial 
barrier, and inflammatory processes induce the differentiation of monocytes into mature 
macrophages. Macrophages phagocytose LDL and become laden with lipids, which give 
them a foamy appearance. The fatty deposits on the inside of the blood vessel wall recruit 
monocytes. They accumulate in the intima and become foam cells. These cells play an 
important role at all stages of atherosclerotic lesion development. The maintenance of foam 
cells and the secretion of cytokines cause the later formation and progression of plaque 
leading to a narrowed artery lumen. Subsequently, foam cells undergo apoptosis or necrosis, 
leaving their lipid-rich content in the walls of the arteries. This contributes to the formation of 
atherosclerotic plaques. Destabilization and rupture of atherosclerotic plaque may lead to 
acute coronary syndromes, and is the typical cause of coronary arteries that causes 
myocardial infarction.(104) 
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AIMS 
Paper I   
The aim of this study was to determine whether there is an increased risk of late 
cardiovascular mortality and morbidity after THA surgery. 
Paper II 
The aim of this study was to determine whether there is an increased risk of cardiovascular 
mortality and morbidity in patients after revision surgery due to aseptic implant loosening 
(cases) compared with patients after THA without revision surgery (controls). 
Paper III 
The aim of this study was to investigate whether THA patients with asymptomatic 
periacetabular osteolysis have an increased long-term risk of CVD compared to THA patients 
without osteolysis and to assess the time to event. 
Paper IV 
The aim of the study was to compare THA patients with and without periacetabular osteolysis 
regarding cardiovascular risk markers and electrocardiography (ECG) findings. 
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PATIENTS AND METHODS 
Paper I 
Study design: a nationwide matched cohort study. Cases were recruited from the SHAR, 
including only patients who underwent cemented THA due to primary OA. Patients treated 
with rarely used implants (occurring <300 times per year in the SHAR) were excluded. Each 
case was matched with 3 random controls that were not present in the SHAR through 
Statistics Sweden’s registry of the total population. Controls were matched to the arthroplasty 
cohort by sex, age ± 5 years, and residence. Residence was defined as municipality, except 
for the 3 largest cities (Stockholm, Malmö, and Gothenburg), where the municipality was 
subdivided into parishes. The matching criteria were chosen to limit socioeconomic 
confounding. All register data were matched with their unique Swedish personal identity 
numbers. Exposure was THA survival of longer than 5 years. The primary outcome was 
cardiovascular mortality after 5 years. Secondary outcomes were total mortality and re-
admission due to cardiovascular events. 
Paper II 
Study design: a nationwide, nested, case-control study. Cases were defined as any patient 
who had undergone reoperation of the treated hip due to aseptic loosening at any time point. 
Each case was matched 4 to 1 with patients from the SHAR. The controls had the same 
exposure time for cardiovascular events, which were only included during that exposure 
period. Subjects with an exposure time of less than 6 years were excluded from the study. 
The study population consisted of patients who had undergone THA due to primary OA 
between 1992 and 2005. Only patients treated with cemented THA with metal-on-PE 
bearings were included. The cups used in THA in the study population consisted of standard 
PE (in Sweden, HXLPE was introduced in 2005). Both modular and non-modular necks were 
used. The exposure period was defined as the period between 5 years after the first surgery 
and 1 year before the first reoperation due to aseptic loosening. Follow-up data on death, 
causes of death, admission to inpatient care, reasons for inpatient care admission and 
reoperation were collected until 2012. Only the first hip was included for patients who 
underwent bilateral surgery. 
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Paper III 
Study design: an observational cohort study. Patients who underwent uncemented THA with 
metal-on-PE articulation performed due to primary OA were included. Only one hip (the first 
treated hip) was included in patients treated with bilateral surgery. All patients underwent 
THA between 1992 and 2007 due to OA; cases had asymptomatic periacetabular osteolysis, 
and controls had no osteolysis. The minimum follow-up time was 10 years due to the slow 
development of osteolysis. The inclusion period lasted from 2012 to 2017. To determine the 
presence of periacetabular osteolysis, CT of the hip region was performed at the inclusion 
visit. Follow-up data after their primary surgery on CVD and causes of death were collected 
until April 2019, a minimum of 12 years. The exclusion criteria were as follows: pain from 
the hip (visual analogue scale) [VAS] score ≥3, with 0 indicating no pain and 10 indicating 
extreme pain), any hip surgery after the primary surgery, ever use of bisphosphonates and 
inflammatory arthritis. 
Paper IV 
In this cross-sectional study, patients who underwent uncemented THA due to OA were 
included. Cases with asymptomatic periacetabular osteolysis after uncemented THA and their 
controls (without periacetabular osteolysis) were compared regarding risk markers for CVD 
and inflammation. The patients included were operated on between 1992 and 2007. The 
presence of periacetabular osteolysis was determined at the inclusion visit by CT between 
2012 and 2017. Biochemical variables were total leukocytes, high-sensitivity C-reactive 
protein (hs-CRP) and lipids. Blood specimens and ECG data were collected at inclusion. All 
patients had metal-on-PE bearings. Only the first hip was included for patients treated with 
bilateral surgery. The exclusion criterion was pain from the hip (VAS score ≥3, with 0 
indicating no pain and 10 indicating extreme pain). Patients treated with revision surgery due 
to periacetabular aseptic loosening were also excluded. 
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Data collection 
SHAR 
The SHAR was founded in 1979 and provides prospective, observational, nationwide data on 
hip arthroplasty.(105) It is the second oldest arthroplasty quality register in the world, with 
the overall aim of improving hip arthroplasty care in Sweden. Individual patient data, such as 
age, sex, diagnosis, surgical approach and type of implant, are collected. Since 1992, personal 
identity numbers have been collected, allowing for patient-specific follow-up, with a 
coverage of 97%, and capturing 98% of all patients treated with THA at all Swedish 
hospitals. One of many important features is that all revision surgeries are collected and 
registered, which makes it possible to investigate complications in detail. 
Statistics Sweden 
 Statistics Sweden is a government agency responsible for coordinating the system for official 
statistics. It provides statistics on the Swedish population for decision-making, debate and 
research. According to the law, the statistics must be official for the public, investigation and 
research. Statistics Sweden started in 1968 and comprises detailed information on all 
individuals’ demographics and places of residence, as well as the population size, changes in 
the population, including births, deaths, immigration, and emigration, and sex, age, civil 
status, country of birth and citizenship. It develops, produces and distributes statistics not 
only to the government and its agencies but also to the public. The statistics have to be 
objective and available to the public; they are divided into 22 subjects and 112 statistical 
areas. 
Cause of death register 
The cause of death register has existed since 1952 and is a high-quality, nearly complete 
register of all deaths in Sweden. It can be linked to other national registers and therefore is an 
important foundation of information for medical research and official statistics. 
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Study designs 
Cohort studies 
Cohort studies are observational, and participants are only observed, without any 
intervention. They are especially appropriate to study rare exposures or exposures for which 
randomization is not possible for practical or ethical reasons. The aim of a cohort study is to 
select study participants who are as similar as possible with the exception of their exposure 
status. Some part of the cohort is exposed to a specific risk factor, and the other part is not. 
All participants must be free of the outcome under investigation and have the potential to 
develop the outcome during the study period. It is a longitudinal type of study; research 
participants are followed over a period of time, often many years. All participants share a 
common characteristic, for example, demographic similarity. The incidence of disease in the 
exposed group is compared with the incidence in the unexposed group. The relative risk is 
used to assess whether the exposure and disease are causally linked. This makes it possible to 
analyse the impact of the exposure and helps to understand what factors increase or decrease 
the likelihood of developing disease. Cohort studies can be performed retrospectively and 
prospectively. In a retrospective cohort study, the exposure and outcome have already 
occurred; therefore, it is less time consuming and costs less. However, if exposure occurred 
long ago, adequate data on exposure might be problematic to collect due to recall bias. The 
data available are not designed with the thought of the study in mind, which may lower the 
quality of the study. The advantages of cohort studies are numerous. A cohort study may 
consist of a large number of participants who can be followed, and it is possible to draw 
conclusions regarding the association between risk factors and the disease outcome. Cohort 
studies are particularly useful at identifying timelines over which exposures can contribute to 
the disease. Participants are free from disease in the beginning of the study; therefore, cohort 
studies are particularly useful for identifying timelines over which exposures can contribute 
to the disease. 
Collecting prospective data in a large group of participants for a long time is complicated, 
time consuming and expensive. Participants may drop out or change behaviour due to 
awareness of being part of a study cohort. Confounding variables in a large-scale study make 
the data analysis complex. It can therefore be challenging to relate cause and effect. 
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Case-Control studies 
In case-control studies, two groups are defined at the start: one with the outcome of 
interest/disease (cases) and one without the outcome/disease (controls). The selection of cases 
should be based on objective inclusion and exclusion criteria from a reliable source, such as a 
disease registry. The controls must be at a similar risk of developing the outcome as the 
cases. Matching controls to cases reduces the effects of confounders, which are variables 
associated with exposure and potentially causes of the outcome. A comparison is performed 
retrospectively to assess whether there is a statistically significant difference in the rate of 
exposure to the risk factor defined in the study between the groups. No intervention is 
undertaken to change the development of the disease. The exposure is determined from each 
of the two groups of individuals. The studies are designed to estimate odds. This study design 
is useful for studying rare conditions or diseases. Studies may be performed with relatively 
few cases. The performance of the study is less time consuming because the condition or 
disease has already occurred. Findings can be obtained relatively quickly. The study design 
allows for the simultaneous observation of multiple risk factors and the establishment of an 
association. The data quality may be lower because it relies on people’s memory (recall bias). 
One problem with selecting cases is that some of those with the disease/outcome may not 
have a formal diagnosis, may not show up for medical care, may be misdiagnosed or may 
have died before getting a diagnosis. Cases and controls should be as similar as possible 
except for their outcome/disease status. An association found between an exposure and a 
disease does not necessarily mean that one factor caused the other. 
Cross-sectional studies 
Cross-sectional studies are performed to assess the presence or absence of a disease/outcome 
and the presence of absence of an exposure at a specific point of time. The design is a type of 
observational study without any intervention done. In case-control studies participants are 
selected based on the outcome status, and in cohort studies participants are selected on the 
exposure status. In cross sectional studies the participants are selected based on inclusion and 
exclusion criteria set just for the study to assess the exposure and the outcomes without the 
need of follow-up. It can be used for surveys and to assess the prevalence of 
diseases/outcomes in clinic-based samples. Conduction and performance of cross-sectional 
studies can be made relatively fast and inexpensive. However due to it´s one-time 
measurement it is difficult to derive casual relationship from cross sectional studies. 
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Statistical methods 
Survival analysis 
Survival analysis is the analysis of time-to-event data and comprises a whole set of tests, 
graphs and models that are used in different study design situations. Data are described as the 
length of time from the time origin to an endpoint of interest. The time origin must be defined 
in a way such that individuals are as similar as possible in terms of the level of disease, for 
example, at the time of diagnosis or surgery. The endpoint, or the event of interest, is also 
supposed to be well defined. The length of time from the time origin to the endpoint is 
calculated. Different objectives of survival analysis include determining patterns of event 
times, comparing distributions of survival times in different groups of individuals, and 
examining factors affecting the risk of an event of interest occurring. All survival analyses 
test how predictive variables predict an outcome variable that measures the time until an 
event. Basic concepts are important in any time-to-event analysis, including censoring, 
survival and hazard functions. 
Censoring 
If the event or outcome of interest does not occur within the study period, the individual will 
be censored, and this may occur due to loss to follow-up or a different event that makes 
follow-up impossible. This type of censoring is called right censoring, while censoring due to 
events or hazards that happened before the time origin is called left censoring. 
Survival and hazard functions: two probabilities are used to describe survival data, i.e., the 
probability of survival and the probability of the hazard. The survival probability is also 
called the survivor function and is the probability that an individual survives from the time 
origin to the endpoint from a hazard/diagnosis. The hazard probability focuses on the 
probability that an individual suffers from an event during a length of time considering time 
in small intervals.  
Kaplan-Meier estimation 
Kaplan-Meier analysis is a method for describing survival graphically and mathematically. 
Three assumptions are used in Kaplan-Meier analysis. The first is that at any time, patients 
who are censored have the same survival prediction as those who continue to be followed. 
The second assumption is that survival probabilities are the same for individuals enrolled 
early and late in the study. The third is that the event occurs within the stated time frame. The 
survival probability at any particular time is calculated by the following formula: for each 
time interval, the survival probability is calculated as the number of individuals surviving 
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divided by the number of patients at risk at each time point. It is also possible to compare 
survival between two or more groups. The method is not suitable to analyse the impact of 
predictors on survival.  
Cox proportional hazards regression model 
To study how several predictors impact survival, regression analysis is required. The Cox 
proportional hazards regression model assesses the association between predictors and 
survival time between two or more groups and is by far the most common model used to 
compare survival. The model also allows the examination of how specified factors impact the 
rate of a particular event at a particular point in time. This rate is commonly referred to as the 
hazard rate. Variables in a Cox regression are named predictors, covariates or independent 
variables; all three expressions have the same meaning. 
Poisson regression 
Poisson regression is a regression model to predict the outcome as the dependent variable and 
a count of events occurring during a given timeframe or space. The count has to have a 
Poisson distribution, meaning that the mean and variance should be the same. 
Log-rank test 
The log-rank test a test to assess whether there are any significant differences in survival 
times between groups being studied and to compare all events occurring at all time points on 
the survival curve. It takes the whole follow-up period into account. Neither the shape of the 
survival curve nor the distribution of survival times is required to compare the survival of 
groups. The same assumptions are used in the log-rank test as in the Kaplan-Meier survival 
analysis. It detects a difference between compared groups when the risk of an event 
happening is consistently larger for one group than another.  
Chi-squared test 
The chi-square test is a statistical hypothesis test designed to analyse categorical data 
comparing two or more proportions from independent groups. The test can also be used to 
test the association between two nominal variables, or one nominal and one ordinal. For small 
samples, Fisher’s exact test is used. 
T-test 
The t-test is a type of hypothesis test to determine whether there is a significant difference 
between the means of two groups, which are related in some features. Three key values are 
needed to calculate a t-test. They are the standard deviation of each group, the mean 
difference between the data sets and the number of values in each group. 
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Mann-Whitney U test 
When the assumption of a normal distribution is not met, non-parametric tests should be used 
for hypothesis testing. The Mann-Whitney U test compares the distribution of two 
independent ordinal variables. It is similar to the t-test but without the assumption of a normal 
distribution. It is not sensitive to outliers because it is designed to use the median and not the 
mean. Because the test uses the median, it works on subjects’ rank order in the overall 
distribution instead of their deviance from the mean or the differences between the means of 
the two groups. 
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Table of statistical tests used  
 Study I Study II Study III Study IV 
     
Survival analysis X X   
Kaplan-Meier 
estimation 
  X  
Cox Proportional 
hazard regression 
X  X  
Poisson regression  X   
Log-rank test   X  
Chi-squared test   X X 
T-test    X 
Mann-Whitney U 
test 
   X 
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RESULTS 
Paper I 
The THA cohort had a lower cardiovascular mortality risk the first 5 to 9 years after surgery 
than the control cohort, the hazard ratio was 0.94 (95% CI 0.89-0.98). After 8.8 years the risk 
increased in the THA cohort, and was higher. Between 9 and 13 years after surgery, the 
hazard ratio was 1.11 (95% CI 1.05-1.17). Furthermore, patients from the THA cohort were 
admitted at a higher frequency to the hospital due to cardiovascular events than the 
controls, with a risk ratio of 1.08 (95% CI 1.06-1.11). 
Paper II 
Patients who had who had surgery for implant loosening after THA due to osteoarthritis had a 
higher risk of cardiovascular morbidity than controls. The risk increase was primarily caused 
by cardiac events. Mean follow-up time was 9.8 years, and the longest follow-up time was 
19.8 years. At 5, 7.5 and 10 years after surgery, 88.3%, 79.5% and 68.9% were still alive. The 
control group had a higher comorbidity burden, but after adjusting for possible confounders, 
cases had an approximately 50% increased relative risk of cardiac events. 
Paper III 
Patients with periacetabular osteolysis had a higher rate of CVD than controls up to 27 years 
after surgery. The female sex was borderline protective against CVD and atherosclerotic 
disease in the crude analysis but lost statistical significance after adjustment. After adjusting 
for different follow-up times with a longer follow up time among cases and for possible 
confounders, we found a 60% increase in risk, but this increase was not statistically 
significant. 
Paper IV 
No differences were found in cardiovascular risk markers or ECG abnormalities between 
THA patients with and without periacetabular osteolysis at a mean follow-up time of 17.7 
and 11.8 years after the primary surgery. Additionally, no differences were found in 
comorbidities, including CVD, with the exception of atrial fibrillation being borderline 
statistically significant. Cases had a longer follow-up time than controls. 
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DISCUSSION 
Study I 
In this nationwide cohort study, we found an increased risk of long-term mortality and 
morbidity in patients surgically treated for OA of the hip compared with controls. This effect 
was mainly ssociated to an increased risk of CVD and an increased risk of hospital admission 
due to cardiovascular events. The results indicate an association of hips surgically treated for 
OA with CVD, an association that, at least to our knowledge, has not been described before. 
More recent studies have shown improved survival in patients after THA compared to 
patients in a matched population.(106, 107) 
Study II 
In this nationwide, nested, case-control study, THA patients after revision surgery due to 
osteolysis and/or implant loosening had a higher risk of cardiovascular morbidity than 
controls, primarily driven by cardiac events. The control group had a higher burden of 
comorbidities, but after adjusting for possible confounders, there was an approximately 50% 
increase in the relative risk of cardiac events in the case group. Few studies have been 
performed in this particular field, but an American study has shown (108) that among patients 
with failed THA, obesity is independently associated with early primary THA failure due to 
aseptic loosening. Obesity is also both an independent risk factor and a risk marker for the 
development of coronary artery disease, heart failure and atrial fibrillation.(109) In addition, 
atrial fibrillation is strongly correlated with inflammation.(110) 
Study III 
Patients with periacetabular osteolysis had a higher rate of CVD than controls up to 27 years 
after surgery, but with CVD occurring among cases later in the observation period. This was 
despite the fact that they were on average younger and healthier at the time of primary THA 
surgery, as reflected by a higher proportion of controls being in ASA class 3 at surgery as 
well as a higher proportion of controls with preoperative CVD events. After adjusting for 
different follow-up times and confounders, we found a 60% increase in risk, but this increase 
was not statistically significant. 
Study IV 
In this cross-sectional study, we could not find any differences in cardiovascular risk markers 
or ECG abnormalities between THA patients with and without periacetabular osteolysis. The 
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mean follow-up time after the primary surgery was 17.7 years in the osteolysis group and 
11.8 years in the non-osteolysis group. We also failed to find any differences in 
comorbidities, including CVD, with the exception of atrial fibrillation, which was borderline 
statistically significant. 
Strengths and limitations 
Strengths of studies I+II 
This is a large-scale population-based cohort with a long follow-up (21 years) of THA. 
Another strength is the increased relative risk among patients despite both self-selection and 
surgeon-selection bias, which means that medically unfit patients will, to a lower degree, be 
inclined for surgery. Health care registers in Sweden are of high quality and offer excellent 
opportunities for epidemiological research. Both the SHAR and Swedish National Patient 
Register (NPR) have good accuracy and completeness.(111) Swedish personal identity 
numbers allow us to identify and link data to the administrative system from where we 
collected the data regarding the cardiovascular diagnoses investigated in this study and death 
dates, which allows patients to be followed throughout the study period until an event, death 
or emigration. All death dates in Sweden are contained in the Swedish cause of death register. 
Unknown deaths occur for patients moving permanently abroad, but it is unlikely that many 
patients would emigrate at an advanced age. To our knowledge, the risk analysis of 
cardiovascular admission to inpatient care among THA patients has only rarely been 
previously investigated. The findings in the current study are consistent with those previously 
reported. In addition, the findings presented in the current study are consistent with 
previously reported rates of hospital admission due to cardiovascular reasons in THA patients 
and matched controls.  
Limitations of studies I+II 
 No adjustments for obesity and smoking were performed. Obesity is associated with an 
increased risk for OA, CVD and atrial fibrillation. There are ICD codes for obesity, but  
rarely used; due to this uncertainty underdiagnosed obesity is still a limitation of the study. 
Smoking is a risk factor for CVD, and there are no data on smoking habits. Lung cancer 
was used as a proxy for comparing smoking in our cohorts, but there was no evidence of 
greater smoking habits in the THA group. Hip OA is often treated with NSAID, both before 
and after surgery, the class of drugs is known to increase the risk of CVD.The increased 
risk of cardiovascular mortality and morbidity could be mediated through NSAID. Intake of 
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NSAID could explain some of the overrepresentation of cardiovascular morbidity in the 
THA group, but controlling for this factor is not possible. Medically unfit patients for 
revision surgery were not identified, resulting in possible misclassification bias and/or 
immortal bias. If included, the effect size would rather decrease than increase because they 
were too sick for undergoing revision surgery and would due to this incorrectly be 
classified as controls. Patients with pain in a previously well-functioning THA may be 
more prone to contact healthcare, and be diagnosed with other conditions, such as CVD. 
This could have increased the effect estimate for the case group. Primary outcome 
definition was stringent; admission due to cardiovascular event had to be at least 2 days to 
be classified as a cardiovascular event. This reduced detection bias reduced as en passant 
registration of cardiovascular diagnoses occurs. It was also minimized by including one 
year before revision surgery to eliminate possible preoperative CVD diagnosis in cases with 
osteolysis/aseptic loosening. 
Strengths of studies III+IV 
This was, to our knowledge, the first study determining asymptomatic THA patients with 
periacetabular osteolysis and comparing them with THA controls regarding CVD, 
cardiovascular risk markers and inflammatory markers. The follow-up time was 27 years, 
patient inclusion was strict, and there was a high degree of completeness of data collection 
and homogeneity. The SHAR is a validated data source with high completeness, including 
both public and private clinics performing THA in Sweden.(105) Both source populations are 
socioeconomically comparable to each other. 
Limitations of studies III+IV 
The samples were relatively small. The number of exclusions was high, as all patients had to 
attend a study visit and undergo CT scans to validate the exposure variable. Several cases 
may have been missed in the exclusion group, thus affecting the outcome. Patients who had 
undergone revision surgery were excluded without analysis prior to revision surgery. 
Including these patients would have increased the sample size as well as the risk of 
experiencing the primary outcome. Additionally, 3 patients were excluded due to pain in the 
hip, which could have been explained by loose components. Pre- or postoperative CVD could 
have been underreported or occurred in locations other than the greater Stockholm area, 
where the medical charts were out of reach. In patients who underwent bilateral hip 
replacement, only the first operated hip was included. There is the potential for an 
accumulated risk if both hips are replaced. Patients who died before screening might have 
  44 
died from CVD, and the status of their hips regarding the presence of osteolysis is not known. 
From a clinical perspective, patients with a severe CVD burden and OA with indications for 
surgery may not undergo surgery because of the high perioperative risk. Patients were not 
stratified regarding the kind of PE used to make the liner. Until 2005, the liner used in these 
sample populations was made of conventional PE. The intention to introduce HXLPE was to 
decrease periprosthetic osteolysis related to PE wear, a large reason for THA revision. In fact, 
all our patients who had developed osteolysis (the cases) underwent surgery with standard 
PE, and none underwent surgery with HXLPE. During 2005, almost all cups implanted in 
Sweden were changed to HXLPE. 
Many attempts have been made to classify osteolysis radiographically.(91, 92, 112-114) In 
this study, osteolysis was not stratified into subgroups, and the amount of wear of the liner 
was not assessed. Additionally, the femoral head size and type of stem were not taken into 
account. Smoking, BMI and the use of corticosteroids and statins were not assessed, which 
could have a potential influence on the development of periacetabular osteolysis and CVD. 
Statins are widely used to reduce cardiovascular morbidity and mortality, experimental 
studies have reported reduced osteoclast activity, and increased bone formation around 
implants.(115) The study population was largely white, and our findings may not be 
generalizable to more ethnically diverse populations. Despite the long and complete follow-
up, the cohorts are relatively small and therefore the power of the analyses is limited. The 
follow-up time differed between the groups; it was significantly longer in the case group, 
which is a major limitation of this analysis, as the development of osteolysis, as well as 
CVD, is time-dependent. 
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GENERAL DISCUSSION 
There is evidence showing that the initiation of OA is linked to vascular pathology.(116) 
Patients with OA may also have a higher risk of CVD.(117) The pathological features of 
CVD include arterial thickening, stiffness and atherosclerosis. These factors lead to deficient 
tissue perforation (ischaemia). The components of advanced OA are multiple ischaemia-
induced bone infarcts and decreased cartilage nutrition. It is unclear whether there is an 
interaction or/and a causal relationship between OA and CVD. The prevalence of CVD 
increases with age, as over time, the heart and vasculature undergo alterations as a result of 
the deregulation of molecular longevity and often due to atherosclerotic disease. OA is also 
associated with ageing as a result of an age‐related loss in the ability of cells and tissues to 
maintain homeostasis, particularly when placed under abnormal stress, such as biomechanical 
overloading of a joint. CVD and OA also have a possible common aetiology in chronic 
inflammation.(118, 119) There is a small increase in mortality 30 to 90 days postoperatively 
after THA.(120) Vascular disease has been reported as the most common cause of death 
among THA patients in general during this period and for up to four years after surgery.(121, 
122) This is later followed by reduced mortality in THA patients up to 13 years post-
operatively.(123, 124) The reduction changes with time into increased mortality and 
morbidity, mainly related to the cardiovascular system.(124) THA has also been associated 
with peripheral arterial disease on long-term follow-up.(125) The higher number of hospital 
admissions for THA patients due to cardiovascular reasons in the first two studies suggests an 
increased overall cardiovascular morbidity for these individuals. Peri-implant osteolysis and 
atherosclerosis have in common the condition currently suggested as long-term, ongoing, 
low-grade inflammation.(126, 127) This further strengthens the results from our cohort, 
where patients with later revision of the artificial joint suffered more cardiac events, and the 
mechanism for this finding can hence have several explanations. In studies 3 and 4, patients 
with asymptomatic periacetabular osteolysis were identified and investigated from a 
previously not studied point of view, at least to our knowledge, in a clinical setting. 
Contradictory to our assumptions from studies 1 and 2, no differences were found in either 
cardiovascular risk markers or levels of inflammatory markers, which opposes the hypothesis 
that higher levels of inflammation would be found in patients with osteolysis. The only 
disease with a borderline statistically significant difference between the groups was atrial 
fibrillation, which is strongly associated with inflammation.(110) The overall lack of 
differences does not exclude osteolysis as a possible risk factor for CVD, as shown in the 
register-based cohort studies. In contrast, the results could indicate that the presence of 
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osteolysis may have a relatively larger impact on the risk of CVD in the long term. Receptor 
activator of nuclear factor κ B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) 
signaling pathway is responsible for the activation and differentiation of bone remodeling 
cells. Stimulation of the system is thought to be a possible trigger of periprosthetic 
osteolysis.(128) Further, vascular calcification is in part regulated by RANKL/RANK/OPG, 
and RANK proteins have been observed in atherosclerotic plaques.(129) The 
RANKL/RANK/OPG is considered as having equal importance in arterial calcification and 
osteolysis in bone (129) and may represent a common pathway in the pathology of OA, 
osteolysis and development of atherosclerosis. 
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CONCLUSIONS 
• Patients with surgically treated OA of the hip may have an increased risk of 
cardiovascular morbidity and mortality many years after the operation. Patients who 
undergo THA and subsequent revision surgery due to loosening and/or osteolysis 
have a higher relative risk of developing cardiovascular events compared to controls. 
This observation may be indicative of common disease pathways, one of which could 
be triggered by local or systemic inflammatory activity. 
• We found a higher rate of CVD in patients with periacetabular osteolysis than in 
patients with no osteolysis after THA. However, the difference was not statistically 
significant, and the longer follow-up of the patients with osteolysis makes the 
comparison difficult. Furthermore, we found no difference in cardiovascular risk 
markers between the groups. 
• A larger sample size and more comparable length in time after surgery are 
recommended in future studies. 
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IMPLICATIONS FOR FUTURE STUDIES 
This thesis provides one of the first assessments of the hypothesized association between 
asymptomatic periacetabular osteolysis and CVD. Insights gained from the studies may be of 
assistance to better understand the long-term effects of THA regarding cardiovascular 
mortality and morbidity. This understanding could help to improve future predictions of the 
long-term impact of THA. Further research is warranted in larger groups of patients with 
osteolysis, in patients treated with bilateral hip replacement, in patients treated with revision 
surgery for aseptic loosening/osteolysis, and in patients unable to undergo surgery due to risk 
factors regarding CVD burden. The approach would gain power if conducted as a multicentre 
study. 
  
   49 
ACKNOWLEDGEMENTS 
 
This thesis becomes a reality with the kind support and help of many individuals. I gratefully 
acknowledge all my colleagues and the staff at Danderyd Hospital.  
I especially want to thank: 
Olof Sköldenberg: main supervisor throughout this thesis. For outstanding support, patience 
and enthusiasm. I sincerely thank him for including me on this journey and allowing me to 
grow. 
Sara Aspberg: co-supervisor. For excellent tutoring, encouragement and everlasting 
kindness. My deepest appreciation and respect for her sharing competence and wisdom with 
me.  
Thomas Eisler: co-supervisor, giving his brilliance, expertise and invaluable contribution, 
my sincere gratitude and respect. 
Max Gordon: co-supervisor, for help and encouragement throughout this thesis. 
Nils Hailer: co-author for invaluable suggestions and contribution in writing. 
André Stark: co-author, for support and help, always with enthusiasm. 
Ola Rolfson: Register Director of the Swedish Hip Arthroplasty Register. 
Mats Salemyr: Head of the Department of Orthopaedics, for generously providing time and 
resources for research. 
Marie Ax, Paula Kelly-Pettersson, Helene Sjöö, and Sofia Grindberg: 
Research nurses at the Department of Ortopedics at Danderyd Hospital for invaluable help. 
Evaldas Laurencikas and Daniel Hallman: radiologists at the Radiology Department at 
Danderyd Hospital for their contribution. 
Gustaf Neander: for encouragement and support. 
Christina Larsson: external mentor for friendship and support.  
The patients: for kindly participate in the studies. 
The Swedish Hip Arthroplasty Register: and all supporting hospitals throughout Sweden. 
Agnes Rysinska: My beyond smart beloved sister, for always helping me. 
 
 
 

   51 

   53 
REFERENCES 
1. Turkiewicz A, Gerhardsson de Verdier M, Engstrom G, Nilsson PM, Mellstrom 
C, Lohmander LS, et al. Prevalence of knee pain and knee OA in southern Sweden and the 
proportion that seeks medical care. Rheumatology (Oxford, England). 2015;54(5):827-35. 
2. Hubertsson J, Petersson IF, Thorstensson CA, Englund M. Risk of sick leave 
and disability pension in working-age women and men with knee osteoarthritis. Annals of the 
rheumatic diseases. 2013;72(3):401-5. 
3. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The 
prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. 
Arthritis and rheumatism. 1987;30(8):914-8. 
4. Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S. The burden of 
musculoskeletal conditions. PloS one. 2014;9(3):e90633. 
5. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. 
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. 
Part I. Arthritis and rheumatism. 2008;58(1):15-25. 
6. Birtwhistle R, Morkem R, Peat G, Williamson T, Green ME, Khan S, et al. 
Prevalence and management of osteoarthritis in primary care: an epidemiologic cohort study 
from the Canadian Primary Care Sentinel Surveillance Network. CMAJ open. 
2015;3(3):E270-5. 
7. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global 
burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. 
Annals of the rheumatic diseases. 2014;73(7):1323-30. 
8. Palazzo C, Nguyen C, Lefevre-Colau MM, Rannou F, Poiraudeau S. Risk 
factors and burden of osteoarthritis. Annals of physical and rehabilitation medicine. 
2016;59(3):134-8. 
9. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-
analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis 
and cartilage. 2005;13(9):769-81. 
10. Hanna FS, Wluka AE, Bell RJ, Davis SR, Cicuttini FM. Osteoarthritis and the 
postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological 
findings. Seminars in arthritis and rheumatism. 2004;34(3):631-6. 
11. Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus 
progestin on knee symptoms and related disability in postmenopausal women: The Heart and 
Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. 
Arthritis and rheumatism. 2001;44(4):811-8. 
12. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. 
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Annals of internal 
medicine. 2000;133(8):635-46. 
13. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of 
osteoarthritis. British medical bulletin. 2013;105:185-99. 
14. Sharma L. Proprioceptive impairment in knee osteoarthritis. Rheumatic 
diseases clinics of North America. 1999;25(2):299-314, vi. 
  54 
15. Jiang L, Tian W, Wang Y, Rong J, Bao C, Liu Y, et al. Body mass index and 
susceptibility to knee osteoarthritis: a systematic review and meta-analysis. Joint, bone, spine 
: revue du rhumatisme. 2012;79(3):291-7. 
16. Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D. 
Association Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, 
and Hand Osteoarthritis: A Population-Based Cohort Study. Arthritis Rheumatol. 
2016;68(8):1869-75. 
17. Karlson EW, Mandl LA, Aweh GN, Sangha O, Liang MH, Grodstein F. Total 
hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable 
risk factors. The American journal of medicine. 2003;114(2):93-8. 
18. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis 
in knee, hip and/or hand: an epidemiological study in the general population with 10 years 
follow-up. BMC musculoskeletal disorders. 2008;9:132. 
19. Kluzek S, Newton JL, Arden NK. Is osteoarthritis a metabolic disorder? British 
medical bulletin. 2015;115(1):111-21. 
20. McAlindon TE, Jacques P, Zhang Y, Hannan MT, Aliabadi P, Weissman B, et 
al. Do antioxidant micronutrients protect against the development and progression of knee 
osteoarthritis? Arthritis and rheumatism. 1996;39(4):648-56. 
21. Parfitt AM, Gallagher JC, Heaney RP, Johnston CC, Neer R, Whedon GD. 
Vitamin D and bone health in the elderly. The American journal of clinical nutrition. 
1982;36(5 Suppl):1014-31. 
22. McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, et 
al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of 
the knee among participants in the Framingham Study. Annals of internal medicine. 
1996;125(5):353-9. 
23. Rasmussen PS. Tibial condylar fractures. Impairment of knee joint stability as 
an indication for surgical treatment. The Journal of bone and joint surgery American volume. 
1973;55(7):1331-50. 
24. Abdel MP, von Roth P, Cross WW, Berry DJ, Trousdale RT, Lewallen DG. 
Total Knee Arthroplasty in Patients With a Prior Tibial Plateau Fracture: A Long-Term 
Report at 15 Years. The Journal of arthroplasty. 2015;30(12):2170-2. 
25. Manidakis N, Dosani A, Dimitriou R, Stengel D, Matthews S, Giannoudis P. 
Tibial plateau fractures: functional outcome and incidence of osteoarthritis in 125 cases. 
International orthopaedics. 2010;34(4):565-70. 
26. Cerejo R, Dunlop DD, Cahue S, Channin D, Song J, Sharma L. The influence 
of alignment on risk of knee osteoarthritis progression according to baseline stage of disease. 
Arthritis and rheumatism. 2002;46(10):2632-6. 
27. Croft P, Coggon D, Cruddas M, Cooper C. Osteoarthritis of the hip: an 
occupational disease in farmers. BMJ (Clinical research ed). 1992;304(6837):1269-72. 
28. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213(3):626-34. 
29. Hannan MT, Felson DT, Pincus T. Analysis of the discordance between 
radiographic changes and knee pain in osteoarthritis of the knee. The Journal of 
rheumatology. 2000;27(6):1513-7. 
   55 
30. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease 
of the joint as an organ. Arthritis and rheumatism. 2012;64(6):1697-707. 
31. Brand RA. 50 Years ago in CORR: Complications in replacement arthroplasty 
of the hip; experience with 68 additional cases Howard Mendelsohn, MD and Bernard N. 
Becker, MD CORR 1955;6:48-53. Clinical orthopaedics and related research. 
2010;468(9):2550-2. 
32. Thould AK, Thould BT. Arthritis in Roman Britain. British medical journal 
(Clinical research ed). 1983;287(6409):1909-11. 
33. Rogers J, Watt I, Dieppe P. Arthritis in Saxon and mediaeval skeletons. British 
medical journal (Clinical research ed). 1981;283(6307):1668-70. 
34. Knight SR, Aujla R, Biswas SP. Total Hip Arthroplasty - over 100 years of 
operative history. Orthop Rev (Pavia). 2011;3(2):e16. 
35. Rysinska A, Skoldenberg O, Garland A, Rolfson O, Aspberg S, Eisler T, et al. 
Aseptic loosening after total hip arthroplasty and the risk of cardiovascular disease: A nested 
case-control study. PloS one. 2018;13(11):e0204391. 
36. Gomez PF, Morcuende JA. Early attempts at hip arthroplasty--1700s to 1950s. 
The Iowa orthopaedic journal. 2005;25:25-9. 
37. Hernigou P. Earliest times before hip arthroplasty: from John Rhea Barton to 
Themistocles Glück. International orthopaedics. 2013;37(11):2313-8. 
38. Smith-Petersen MN. The classic: Evolution of mould arthroplasty of the hip 
joint by M. N. Smith-Petersen, J. Bone Joint Surg. 30B:L:59, 1948. Clinical orthopaedics and 
related research. 1978(134):5-11. 
39. The classic: Arthroplasty of the hip: a new operation by John Charnley, M.B., 
B. Sc. Manc., F.R.C.S. Reprinted from Lancet pp. 1129-32, 196l. Clinical orthopaedics and 
related research. 1973(95):4-8. 
40. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year 
survivorship of two thousand consecutive primary Charnley total hip replacements: factors 
affecting survivorship of acetabular and femoral components. The Journal of bone and joint 
surgery American volume. 2002;84-a(2):171-7. 
41. Callaghan JJ, Albright JC, Goetz DD, Olejniczak JP, Johnston RC. Charnley 
total hip arthroplasty with cement. Minimum twenty-five-year follow-up. The Journal of 
bone and joint surgery American volume. 2000;82(4):487-97. 
42. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip 
replacement. Lancet (London, England). 2007;370(9597):1508-19. 
43. Hasan K, Shankar S, Sharma A, Carter A, Zaidi R, Cro S, et al. Hip surgery and 
its evidence base: progress over a decade? Journal of orthopaedics and traumatology : official 
journal of the Italian Society of Orthopaedics and Traumatology. 2016;17(4):291-5. 
44. Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. Lancet (London, 
England). 2012;380(9855):1768-77. 
45. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and 
revision hip and knee arthroplasty in the United States from 2005 to 2030. The Journal of 
bone and joint surgery American volume. 2007;89(4):780-5. 
  56 
46. Svenska höftprotesregistret. Svenska höftprotesregistret 2019 [Available from: 
https://shpr.registercentrum.se/. 
47. Delaunay C. Registries in orthopaedics. Orthop Traumatol Surg Res. 
2015;101(1 Suppl):S69-75. 
48. Judet R, Siguier M, Brumpt B, Judet T. A noncemented total hip prosthesis. 
Clinical orthopaedics and related research. 1978(137):76-84. 
49. Muratoglu OK, Bragdon CR, O'Connor DO, Jasty M, Harris WH, Gul R, et al. 
Unified wear model for highly crosslinked ultra-high molecular weight polyethylenes 
(UHMWPE). Biomaterials. 1999;20(16):1463-70. 
50. Joyce TJ. CORR Insights(R): the John Charnley Award: highly crosslinked 
polyethylene in total hip arthroplasty decreases long-term wear: a double-blind randomized 
trial. Clinical orthopaedics and related research. 2015;473(2):439-40. 
51. Garcia-Rey E, Garcia-Cimbrelo E, Cruz-Pardos A. New polyethylenes in total 
hip replacement: A ten- to 12-year follow-up study. The bone & joint journal. 2013;95-
b(3):326-32. 
52. Willmann G. Ceramics for total hip replacement--what a surgeon should know. 
Orthopedics. 1998;21(2):173-7. 
53. Willmann G. Ceramic femoral head retrieval data. Clinical orthopaedics and 
related research. 2000(379):22-8. 
54. Mahiques-Segura G, Lizaur-Utrilla A, Vizcaya-Moreno MF, Miralles-Munoz 
FA, Lopez-Prats FA. A Comparison Study of the Outcomes of Ceramic-on-Ceramic Total 
Hip Arthroplasty in Young vs Older Patients: A Minimum 10-Year Follow-Up Prospective 
Matched Study. The Journal of arthroplasty. 2019;34(8):1731-5. 
55. Malviya A, Holland JP. Pseudotumours associated with metal-on-metal hip 
resurfacing: 10-year Newcastle experience. Acta orthopaedica Belgica. 2009;75(4):477-83. 
56. Kwon YM, Thomas P, Summer B, Pandit H, Taylor A, Beard D, et al. 
Lymphocyte proliferation responses in patients with pseudotumors following metal-on-metal 
hip resurfacing arthroplasty. J Orthop Res. 2010;28(4):444-50. 
57. Willert HG, Buchhorn GH, Fayyazi A, Flury R, Windler M, Koster G, et al. 
Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical 
and histomorphological study. The Journal of bone and joint surgery American volume. 
2005;87(1):28-36. 
58. Ollivere B, Darrah C, Barker T, Nolan J, Porteous MJ. Early clinical failure of 
the Birmingham metal-on-metal hip resurfacing is associated with metallosis and soft-tissue 
necrosis. The Journal of bone and joint surgery British volume. 2009;91(8):1025-30. 
59. Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons 
CL, et al. Pseudotumours associated with metal-on-metal hip resurfacings. The Journal of 
bone and joint surgery British volume. 2008;90(7):847-51. 
60. Persson A, Eisler T, Boden H, Krupic F, Skoldenberg O, Muren O. Revision 
for Symptomatic Pseudotumor After Primary Metal-on-Polyethylene Total Hip Arthroplasty 
with a Standard Femoral Stem. The Journal of bone and joint surgery American volume. 
2018;100(11):942-9. 
   57 
61. Bradberry SM, Wilkinson JM, Ferner RE. Systemic toxicity related to metal hip 
prostheses. Clin Toxicol (Phila). 2014;52(8):837-47. 
62. Salo PP, Honkanen PB, Ivanova I, Reito A, Pajamaki J, Eskelinen A. High 
prevalence of noise following Delta ceramic-on-ceramic total hip arthroplasty. The bone & 
joint journal. 2017;99-b(1):44-50. 
63. Hirose S, Otsuka H, Morishima T, Sato K. Outcomes of Charnley total hip 
arthroplasty using improved cementing with so-called second- and third-generation 
techniques. J Orthop Sci. 2012;17(2):118-23. 
64. Donaldson AJ, Thomson HE, Harper NJ, Kenny NW. Bone cement 
implantation syndrome. British journal of anaesthesia. 2009;102(1):12-22. 
65. Kallos T. Impaired arterial oxygenation associated with use of bone cement in 
the femoral shaft. Anesthesiology. 1975;42(2):210-5. 
66. Wheelwright EF, Byrick RJ, Wigglesworth DF, Kay JC, Wong PY, Mullen JB, 
et al. Hypotension during cemented arthroplasty. Relationship to cardiac output and fat 
embolism. The Journal of bone and joint surgery British volume. 1993;75(5):715-23. 
67. Parvizi J, Holiday AD, Ereth MH, Lewallen DG. The Frank Stinchfield Award. 
Sudden death during primary hip arthroplasty. Clinical orthopaedics and related research. 
1999(369):39-48. 
68. Duncan JA. Intra-operative collapse or death related to the use of acrylic 
cement in hip surgery. Anaesthesia. 1989;44(2):149-53. 
69. The Glossary of Prosthodontic Terms: Ninth Edition. J Prosthet Dent. 
2017;117(5s):e1-e105. 
70. Albrektsson T, Brånemark PI, Hansson H-A, Jj L. Osseointegrated Titanium 
Implants: Requirements for Ensuring a Long-Lasting, Direct Bone-to-Implant Anchorage in 
Man. Acta orthopaedica Scandinavica. 1981;52:155-70. 
71. Bauer TW, Geesink RC, Zimmerman R, McMahon JT. Hydroxyapatite-coated 
femoral stems. Histological analysis of components retrieved at autopsy. The Journal of bone 
and joint surgery American volume. 1991;73(10):1439-52. 
72. Tonino A, Oosterbos C, Rahmy A, Therin M, Doyle C. Hydroxyapatite-coated 
acetabular components. Histological and histomorphometric analysis of six cups retrieved at 
autopsy between three and seven years after successful implantation. The Journal of bone and 
joint surgery American volume. 2001;83(6):817-25. 
73. Chambers B, St Clair SF, Froimson MI. Hydroxyapatite-coated tapered 
cementless femoral components in total hip arthroplasty. The Journal of arthroplasty. 
2007;22(4 Suppl 1):71-4. 
74. Herrera A, Mateo J, Gil-Albarova J, Lobo-Escolar A, Ibarz E, Gabarre S, et al. 
Cementless hydroxyapatite coated hip prostheses. Biomed Res Int. 2015;2015:386461. 
75. Gibon E, Amanatullah DF, Loi F, Pajarinen J, Nabeshima A, Yao Z, et al. The 
biological response to orthopaedic implants for joint replacement: Part I: Metals. J Biomed 
Mater Res B Appl Biomater. 2017;105(7):2162-73. 
76. Gibon E, Cordova LA, Lu L, Lin TH, Yao Z, Hamadouche M, et al. The 
biological response to orthopedic implants for joint replacement. II: Polyethylene, ceramics, 
  58 
PMMA, and the foreign body reaction. J Biomed Mater Res B Appl Biomater. 
2017;105(6):1685-91. 
77. Pastides PS, Dodd M, Sarraf KM, Willis-Owen CA. Trunnionosis: A pain in 
the neck. World J Orthop. 2013;4(4):161-6. 
78. Sandgren B, Crafoord J, Olivecrona H, Garellick G, Weidenhielm L. Risk 
factors for periacetabular osteolysis and wear in asymptomatic patients with uncemented total 
hip arthroplasties. ScientificWorldJournal. 2014;2014:905818. 
79. Oparaugo PC, Clarke IC, Malchau H, Herberts P. Correlation of wear debris-
induced osteolysis and revision with volumetric wear-rates of polyethylene: a survey of 8 
reports in the literature. Acta Orthop Scand. 2001;72(1):22-8. 
80. Harris WH. Wear and Periprosthetic Osteolysis: The Problem. Clinical 
Orthopaedics and Related Research®. 2001;393:66-70. 
81. Jain S, Camacho P. Use of bone turnover markers in the management of 
osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2018;25(6):366-72. 
82. Katsimbri P. The biology of normal bone remodelling. Eur J Cancer Care 
(Engl). 2017;26(6). 
83. Aspenberg P, van der Vis H. Fluid pressure may cause periprosthetic osteolysis. 
Particles are not the only thing. Acta orthopaedica Scandinavica. 1998;69(1):1-4. 
84. Mavrogenis AF, Dimitriou R, Parvizi J, Babis GC. Biology of implant 
osseointegration. J Musculoskelet Neuronal Interact. 2009;9(2):61-71. 
85. Howie DW, Neale SD, Haynes DR, Holubowycz OT, McGee MA, Solomon 
LB, et al. Periprosthetic osteolysis after total hip replacement: molecular pathology and 
clinical management. Inflammopharmacology. 2013;21(6):389-96. 
86. Willert HG, Semlitsch M. Reactions of the articular capsule to wear products of 
artificial joint prostheses. J Biomed Mater Res. 1977;11(2):157-64. 
87. Harris WH. Osteolysis and particle disease in hip replacement. A review. Acta 
orthopaedica Scandinavica. 1994;65(1):113-23. 
88. Paprosky WG, Perona PG, Lawrence JM. Acetabular defect classification and 
surgical reconstruction in revision arthroplasty. A 6-year follow-up evaluation. The Journal of 
arthroplasty. 1994;9(1):33-44. 
89. Saleh KJ, Holtzman J, Gafni AL, Jaroszynski G, Wong P, Woodgate I, et al. 
Development, test reliability and validation of a classification for revision hip arthroplasty. J 
Orthop Res. 2001;19(1):50-6. 
90. Gustilo RB, Pasternak HS. Revision total hip arthroplasty with titanium 
ingrowth prosthesis and bone grafting for failed cemented femoral component loosening. 
Clinical orthopaedics and related research. 1988(235):111-9. 
91. Puri L, Wixson RL, Stern SH, Kohli J, Hendrix RW, Stulberg SD. Use of 
helical computed tomography for the assessment of acetabular osteolysis after total hip 
arthroplasty. The Journal of bone and joint surgery American volume. 2002;84-a(4):609-14. 
92. Claus AM, Totterman SM, Sychterz CJ, Tamez-Pena JG, Looney RJ, Engh 
CA, Sr. Computed tomography to assess pelvic lysis after total hip replacement. Clinical 
orthopaedics and related research. 2004(422):167-74. 
   59 
93. Lohmann CH, Rampal S, Lohrengel M, Singh G. Imaging in peri-prosthetic 
assessment: an orthopaedic perspective. EFORT Open Rev. 2017;2(5):117-25. 
94. Livermore J, Ilstrup D, Morrey B. Effect of femoral head size on wear of the 
polyethylene acetabular component. The Journal of bone and joint surgery American volume. 
1990;72(4):518-28. 
95. Martell JM, Berdia S. Determination of polyethylene wear in total hip 
replacements with use of digital radiographs. The Journal of bone and joint surgery American 
volume. 1997;79(11):1635-41. 
96. Selvik G. Roentgen stereophotogrammetric analysis. Acta Radiol. 
1990;31(2):113-26. 
97. Global, regional, and national incidence, prevalence, and years lived with 
disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1545-602. 
98. Ignarro LJ, Balestrieri ML, Napoli C. Nutrition, physical activity, and 
cardiovascular disease: an update. Cardiovascular research. 2007;73(2):326-40. 
99. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with 
drugs to lower blood pressure and blood cholesterol based on an individual's absolute 
cardiovascular risk. Lancet (London, England). 2005;365(9457):434-41. 
100. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. 
Reduction in incidence of coronary heart disease. Jama. 1984;251(3):351-64. 
101. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol 
and risk of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Jama. 
1986;256(20):2823-8. 
102. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. 
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from 
genetic, epidemiologic, and clinical studies. A consensus statement from the European 
Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. 
103. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. 
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern 
recognition receptors of innate immunity. Circulation research. 2011;108(2):235-48. 
104. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et 
al. Atherosclerosis. Nature reviews Disease primers. 2019;5(1):56. 
105. Karrholm J. The Swedish Hip Arthroplasty Register (www.shpr.se). Acta 
orthopaedica. 2010;81(1):3-4. 
106. Barrett J, Losina E, Baron JA, Mahomed NN, Wright J, Katz JN. Survival 
following total hip replacement. The Journal of bone and joint surgery American volume. 
2005;87(9):1965-71. 
107. Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset SE. Mortality after 
total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty 
Register. Acta orthopaedica Scandinavica. 2000;71(1):19-27. 
  60 
108. Goodnough LH, Finlay AK, Huddleston JI, 3rd, Goodman SB, Maloney WJ, 
Amanatullah DF. Obesity Is Independently Associated With Early Aseptic Loosening in 
Primary Total Hip Arthroplasty. The Journal of arthroplasty. 2018;33(3):882-6. 
109. Mandviwala T, Khalid U, Deswal A. Obesity and Cardiovascular Disease: a 
Risk Factor or a Risk Marker? Curr Atheroscler Rep. 2016;18(5):21. 
110. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial 
fibrillation. Nat Rev Cardiol. 2015;12(4):230-43. 
111. Cnudde P, Rolfson O, Nemes S, Karrholm J, Rehnberg C, Rogmark C, et al. 
Linking Swedish health data registers to establish a research database and a shared decision-
making tool in hip replacement. BMC musculoskeletal disorders. 2016;17(1):414. 
112. Howie DW, Neale SD, Stamenkov R, McGee MA, Taylor DJ, Findlay DM. 
Progression of acetabular periprosthetic osteolytic lesions measured with computed 
tomography. The Journal of bone and joint surgery American volume. 2007;89(8):1818-25. 
113. Egawa H, Ho H, Hopper RH, Jr., Engh CA, Jr., Engh CA. Computed 
tomography assessment of pelvic osteolysis and cup-lesion interface involvement with a 
press-fit porous-coated acetabular cup. The Journal of arthroplasty. 2009;24(2):233-9. 
114. Suh DH, Han SB, Yun HH, Chun SK, Shon WY. Characterization of 
progression of pelvic osteolysis after cementless total hip arthroplasty: computed 
tomographic study. The Journal of arthroplasty. 2013;28(10):1851-5. 
115. Lubbeke A, Garavaglia G, Rothman KJ, Bonvin A, Roussos C, Miozzari H, et 
al. Statins may reduce femoral osteolysis in patients with total Hip arthroplasty. J Orthop Res. 
2013;31(5):814-20. 
116. Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford, 
England). 2007;46(12):1763-8. 
117. Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular 
disease: a meta-analysis of observational studies. Scientific reports. 2016;6:39672. 
118. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship 
between osteoarthritis and cardiovascular disease in a population health survey: a cross-
sectional study. BMJ open. 2013;3(5). 
119. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and 
disease specific mortality in patients with knee or hip osteoarthritis: population based cohort 
study. BMJ (Clinical research ed). 2011;342:d1165. 
120. Berstock JR, Beswick AD, Lenguerrand E, Whitehouse MR, Blom AW. 
Mortality after total hip replacement surgery: A systematic review. Bone & joint research. 
2014;3(6):175-82. 
121. Blom A, Pattison G, Whitehouse S, Taylor A, Bannister G. Early death 
following primary total hip arthroplasty: 1,727 procedures with mechanical thrombo-
prophylaxis. Acta orthopaedica. 2006;77(3):347-50. 
122. Gaston MS, Amin AK, Clayton RA, Brenkel IJ. Does a history of cardiac 
disease or hypertension increase mortality following primary elective total hip arthroplasty? 
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 
2007;5(5):260-5. 
   61 
123. Pedersen AB, Baron JA, Overgaard S, Johnsen SP. Short- and long-term 
mortality following primary total hip replacement for osteoarthritis: a Danish nationwide 
epidemiological study. The Journal of bone and joint surgery British volume. 
2011;93(2):172-7. 
124. Gordon M, Rysinska A, Garland A, Rolfson O, Aspberg S, Eisler T, et al. 
Increased Long-Term Cardiovascular Risk After Total Hip Arthroplasty: A Nationwide 
Cohort Study. Medicine. 2016;95(6):e2662. 
125. Chou TY, Su TW, Jou HJ, Yang PY, Chen HJ, Muo CH, et al. Increased risk of 
peripheral arterial disease after hip replacement: an 11-year retrospective population-based 
cohort study. Medicine. 2015;94(19):e870. 
126. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 
Suppl):C7-12. 
127. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial 
tree: players and layers. Circulation research. 2015;116(2):307-11. 
128. Goodman SB, Gallo J. Periprosthetic Osteolysis: Mechanisms, Prevention and 
Treatment. J Clin Med. 2019;8(12). 
129. Alexander MY. RANKL links arterial calcification with osteolysis. Circulation 
research. 2009;104(9):1032-4. 
 
 
 
 
 
 
 
 
 
 
 
 
STUDIES I-IV 
